We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

163 hedge funds and large institutions have $974M invested in GenMark Diagnostics, Inc in 2020 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 52 increasing their positions, 56 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 20

10% more funds holding

Funds holding: 148163 (+15)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

3% less capital invested

Capital invested by funds: $1,000M → $974M (-$25.6M)

7% less repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 56

73% less call options, than puts

Call options by funds: $1.63M | Put options by funds: $6.01M

Holders
163
Holders Change
+15
Holders Change %
+10.14%
% of All Funds
3.29%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
35
Increased
52
Reduced
56
Closed
20
Calls
$1.63M
Puts
$6.01M
Net Calls
-$4.38M
Net Calls Change
-$5.96M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$151M +$3.2M +209,435 +2%
BlackRock
2
BlackRock
New York
$76.1M -$714K -46,704 -0.9%
CCM
3
Consonance Capital Management
New York
$75.3M -$24.4M -1,594,618 -23%
RG
4
Redmile Group
California
$66.9M -$2.9M -189,800 -4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$62M +$9.87M +645,589 +17%
Renaissance Technologies
6
Renaissance Technologies
New York
$38.4M +$506K +33,100 +1%
Macquarie Group
7
Macquarie Group
Australia
$38.2M +$20.9M +1,368,565 +104%
State Street
8
State Street
Massachusetts
$28M -$212K -13,846 -0.7%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$27.2M -$513K -33,554 -2%
Alyeska Investment Group
10
Alyeska Investment Group
Illinois
$21.5M +$9.07M +593,548 +64%
WA
11
Wasatch Advisors
Utah
$21.5M +$3.56M +233,290 +18%
BG
12
Bellevue Group
Switzerland
$17.9M -$3.45M -225,473 -15%
N
13
Nuveen
North Carolina
$17.1M +$7.5M +491,048 +69%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$17.1M +$367K +23,996 +2%
Bank of America
15
Bank of America
North Carolina
$15.3M +$854K +55,888 +5%
William Blair Investment Management
16
William Blair Investment Management
Illinois
$15.1M +$6.65M +435,451 +69%
Goldman Sachs
17
Goldman Sachs
New York
$14.4M +$1.18M +77,352 +8%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$14.4M -$3.71M -242,791 -19%
Northern Trust
19
Northern Trust
Illinois
$13.7M -$303K -19,835 -2%
GIPM
20
G2 Investment Partners Management
New York
$11.7M +$1.63M +106,461 +15%
Invesco
21
Invesco
Georgia
$11.3M +$12.1M +794,441 New
AC
22
Armistice Capital
New York
$11.2M +$12.1M +792,000 New
HighTower Advisors
23
HighTower Advisors
Illinois
$11M -$3.03M -198,552 -20%
RI
24
RTW Investments
New York
$10.8M -$2.63M -172,212 -18%
Ameriprise
25
Ameriprise
Minnesota
$10.5M +$22.9K +1,501 +0.2%

GNMK Hedge Fund Activity: Q3 2020 in Review

163 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2020, worth a combined $974M — down 2.6% from $1,000M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new GNMK positions and 20 closed out — a net gain of 15 holders — while 52 added to existing stakes and 56 trimmed.

The largest buyer was Macquarie Group, adding an estimated $20.9M. The largest seller was Consonance Capital Management, cutting an estimated $24.4M.

  • 163 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2020, up from 148 in Q2 2020.
  • Funds reported $974M of GenMark Diagnostics, Inc stock for Q3 2020, down 2.6% quarter-over-quarter.
  • 35 funds opened new GenMark Diagnostics, Inc positions in Q3 2020 and 20 closed out, a net change of +15 holders.
  • The largest GenMark Diagnostics, Inc buyer in Q3 2020 was Macquarie Group, an estimated $20.9M added.
  • The largest GenMark Diagnostics, Inc seller in Q3 2020 was Consonance Capital Management, an estimated $24.4M sold.

Based on aggregated 13F filings for Q3 2020.